{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:19:31Z","timestamp":1787566771234,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005937","name":"Cheng Hsin General Hospital","doi-asserted-by":"publisher","award":["CHNDMU-115-02"],"award-info":[{"award-number":["CHNDMU-115-02"]}],"id":[{"id":"10.13039\/501100005937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-D-115176"],"award-info":[{"award-number":["TSGH-D-115176"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eclinm.2026.104117","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:43:44Z","timestamp":1785228224000},"page":"104117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["SGLT2 inhibitors and risk of distant metastasis in patients with breast cancer and type 2 diabetes: a target trial emulation with biological plausibility analysis"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0280-6417","authenticated-orcid":false,"given":"Po-Huang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8937-6105","authenticated-orcid":false,"given":"Wei-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Jie","family":"Jhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0552-569X","authenticated-orcid":false,"given":"Hsin-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Hsuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6061-5168","authenticated-orcid":false,"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104117_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2026.104117_bib2","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO\u2013ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104117_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2009.27.3011","article-title":"Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis","volume":"29","author":"Peairs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104117_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.eclinm.2026.104117_bib5","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104117_bib6","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104117_bib7","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.eclinm.2026.104117_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","article-title":"SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia","volume":"7","author":"Nasiri","year":"2019","journal-title":"Cancer Metab"},{"key":"10.1016\/j.eclinm.2026.104117_bib9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose Co-Transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.eclinm.2026.104117_bib10","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eclinm.2026.104117_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s43018-023-00704-x","article-title":"Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation","volume":"5","author":"Rogava","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.eclinm.2026.104117_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaoncol.2025.5869","article-title":"Sodium-Glucose cotransporter 2 inhibitors for patients with prostate cancer undergoing hormone therapy","volume":"12","author":"Shi","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2026.104117_bib13","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1172\/JCI96153","article-title":"Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer","volume":"128","author":"Siegel","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eclinm.2026.104117_bib14","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.eclinm.2026.104117_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2026.104117_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.eclinm.2026.104117_bib17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.104117_bib18","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial-the TARGET statement","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2026.104117_bib19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0962280211403603","article-title":"Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease","volume":"22","author":"Danaei","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.eclinm.2026.104117_bib20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.eclinm.2026.104117_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.eclinm.2026.104117_bib22","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2026.104117_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.eclinm.2026.104117_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-Value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2026.104117_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"10.1016\/j.eclinm.2026.104117_bib26","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.eclinm.2026.104117_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.freeradbiomed.2023.05.033","article-title":"AMPK negatively regulates RANKL-induced osteoclast differentiation by controlling oxidative stress","volume":"205","author":"Tanaka","year":"2023","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.eclinm.2026.104117_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105379","article-title":"AMPK\u03b11 negatively regulates osteoclastogenesis and mitigates pathological bone loss","volume":"299","author":"Ribeiro","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1016\/j.eclinm.2026.104117_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.20892\/j.issn.2095-3941.2019.0210","article-title":"Metabolic reprogramming in triple-negative breast cancer","volume":"17","author":"Wang","year":"2020","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.eclinm.2026.104117_bib30","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eclinm.2026.104117_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/pds.4681","article-title":"Predictive model algorithms identifying early and advanced stage ER+\/HER2\u2212 breast cancer in claims data","volume":"28","author":"Beachler","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:26:18Z","timestamp":1787559978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026003706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S2589537026003706"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104117","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitors and risk of distant metastasis in patients with breast cancer and type 2 diabetes: a target trial emulation with biological plausibility analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104117"}}